| 2022 | Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party. |
| 2022 | Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. |
| 2022 | Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study |
| 2022 | Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results |
| 2022 | Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909). |
| 2022 | Impact of ixazomib-lenalidomide-dexamethasone therapy onoverall survival in multiple myeloma patients: Analysis of theemerging-markets subgroup of the TOURMALINE-MM1 trial. |
| 2022 | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia |
| 2022 | Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea. |
| 2022 | Low-dose abdominopelvic computed tomography in patients with lymphoma: An image quality and radiation dose reduction study |
| 2022 | Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.. |
| 2022 | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. |
| 2022 | Busulfan, Melphalan, and Etoposide (Bume) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL |
| 2022 | Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.Y |
| 2021 | Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. |
| 2021 | Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). |
| 2020 | A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. |
| 2020 | The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP |
| 2020 | Incorporating hematopoietic stem-celltransplantation after second-line carfilzomiblenalidomide-dexamethasone |
| 2020 | ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia |
| 2020 | Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia |
| 2020 | Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults |
| 2020 | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis |
| 2019 | Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. Park SS, Eom HS, Kim JS, Koh Y, Choi CW, Lee JJ, Kim K, Suh C, Lee JH, Min CK; Korean Multiple Myeloma Working Party. Jpn J Clin Oncol. 2019 Jan 1;49(1):92-95. doi: 10.1093/jjco/hyy177. |
| 2019 | Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, Duarte GO, Fantl DB, Navarro JR, Conte G, Gomez-Almaguer D, Ruiz-Argüelles GJ, Kim K, Shimizu K, Chen W, Huang SY, Chng WJ, Chim CS, Nawarawong W, Durie B. Ann Hematol. 2019 Feb 6. doi: 10.1007/s00277-019-03602-4. [Epub ahead of print] |
| 2019 | Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Blood. 2019 Feb 28 |
| 2019 | Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Br J Haematol. 2019 Mar;184(5):735-743 |
| 2019 | A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. Park SS, Kim K, Kim SJ, Lee JH, Yoon SS, Mun YC, Lee JJ, Eom HS, Kim JS, Min CK; Korean Multiple Myeloma Working Party. Biol Blood Marrow Transplant. 2019 Mar 23. pii: S1083-8791(19)30192-2. doi: 10.1016/j.bbmt.2019.03.016. [Epub ahead of print] |
| 2019 | Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28 |
| 2019 | Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, López-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6. |
| 2019 | Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH. Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6 |
| 2019 | Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. Erratum in: JAMA. 2019 Aug 27;322(8):785 |
| 2019 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Lancet. 2019 Jan 19;393(10168):253-264. |
| 2019 | A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. Park SS, Kim K, Kim SJ, Lee JH, Yoon SS, Mun YC, Lee JJ, Eom HS, Kim JS, Min CK; Korean Multiple Myeloma Working Party. Biol Blood Marrow Transplant. 2019 Jul;25(7):1312-1319. doi: 10.1016/j.bbmt.2019.03.016. Epub 2019 Mar 23. |
| 2019 | Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. Soekojo CY, Kim K, Huang SY, Chim CS, Takezako N, Asaoku H, Kimura H, Kosugi H, Sakamoto J, Gopalakrishnan SK, Nagarajan C, Wei Y, Moorakonda R, Lee SL, Lee JJ, Yoon SS, Kim JS, Min CK, Lee JH, Durie B, Chng WJ. Blood Cancer J. 2019 Oct 8;9(10):83. doi: 10.1038/s41408-019-0245-1. |
| 2019 | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Oh SY, Kim WS, Kim JS, Kim SJ, Yoon DH, Yang DH, Lee WS, Kim HJ, Yhim HY, Jeong SH, Won JH, Lee S, Kong JH, Lim SN, Ji JH, Kwon KA, Lee GW, Lee JH, Lee HS, Shin HJ, Suh C. Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7. |
| 2019 | Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Fujisaki T, Ishikawa T, Takamatsu H, Suzuki K, Min CK, Lee JH, Wang J, Carson R, Crist W, Qi M, Nagafuji K. Ann Hematol. 2019 Oct 16. doi: 10.1007/s00277-019-03794-9. [Epub ahead of print] |
| 2018 | Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Tan D, Lee JH, Chen W, Shimizu K, Hou J, Suzuki K, Nawarawong W, Huang SY, Sang Chim C, Kim K, Kumar L, Malhotra P, Chng WJ, Durie B; Asian Myeloma Network. Leuk Lymphoma. 2018 Feb 2:1-13 |
| 2018 | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS; Korean Multiple Myeloma Working Party. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30019-3. doi: 10.1016/j.bbmt.2018.01.004. [Epub ahead of print] |
| 2018 | Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Oncotarget. 2017 Sep 18;8(54):92171-92182 |
| 2018 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12 |
| 2018 | Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. |
| 2018 | Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Korean J Intern Med. 2018 Jan;33(1):168-175 2018 |
| 2018 | A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T. Leukemia. 2018 Jun;32(6):1404-1413 |
| 2018 | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. Lee GW, Park SW, Go SI, Kim HG, Kim MK, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Kim H, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Yi HG, Moon JH, Choi CW, Kim SH, Kim BS, Park MR, Shim H, Song MK, Kim Y, Kim K. Acta Haematol. 2018 Sep 25;140(3):146-156. doi: 10.1159/000490488. [Epub ahead of print] |
| 2018 | Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7. |
| 2018 | Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Br J Haematol. 2018 Dec 12. doi: 10.1111/bjh.15700. [Epub ahead of print] PMID: 30548250 |
| 2018 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Lancet. 2018 Dec 10. pii: S0140-6736(18)33003-4. doi: 10.1016/S0140-6736(18)33003-4. [Epub ahead of print] |
| 2017 | Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Seo JY, Hong J, Chun K, Jeong J, Cho H, Kim KH, Park J, Ahn JY, Park PW, Lee JH. Leuk Lymphoma. 2017 Feb;58(2):357-365. |
| 2017 | Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the FIRST Trial. Lu J, Lee JH, Huang SY, Qiu L, Lee JJ, Liu T, Yoon SS, Kim K, Shen ZX, Eom HS, Chen WM, Min CK, Kim HJ, Lee JO, Kwak JY, Yiu W, Chen G, Ervin-Haynes A, Hulin C, Facon T. Br J Hematol 2017 Mar;176(5):743-749 |
| 2017 | Deacetylase Inhibitors: an Advance in Myeloma Therapy? Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Alsina M, Richardson PG. Expert Rev Hematol. 2017 Mar;10(3):229- |
| 2017 | Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Kwon J, Min CK, Kim K, Han JJ, Moon JH, Kang HJ, Eom HS, Kim MK, Kim HJ, Yoon DH, Lee JO, Lee WS, Lee JH, Lee JJ, Choi |
| 2017 | YS, Kim SH, Yoon SS. Cancer Med. 2017 Jan;6(1):100-108 |
| 2017 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Kim MK, Kim K, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Kim YS, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Kim H, Yi HG, Moon JH, Choi CW, Kim SH, Joo YD, Kim HG, Kim BS, Park MR, Song MK, Kim SY. Oncotarget. 2017 Jun 6;8(23):37605-3761 |
| 2017 | Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. Suh KJ, Cheong JW, Kim I, Kim HJ, Shin DY, Koh Y, Yoon SS, Min YH, Ahn JS, Kim YK, Lee YG, Lee JO, Bang SM, Mun YC, Seong CM, Park Y, Kim BS, Hong J, Park J, Lee JH, Kim SY, Lee HG. PLoS One. 2016 Nov 8;11(11): |
| 2017 | Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS working party. Kim DJ, Lee HS, Moon JH, Sohn SK, Kim HJ, Cheong JW, Jo DY, Kim H, Lee H, Bang SM, Lee WS, Park Y, Lee MH, Lee JH, Bae SH, Kim MK; Korean Society of Hematology AML/MDS Working Party. Oncotarget. 2017 May 29;8(45):79414-794249. doi: 10.18632/oncotarget.18258. [Epub ahead of print] |
| 2017 | The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Jung SH, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, Sohn SK, Choi CW, Lee HS, Kim HJ, Shin HJ, Bang SM, Yoon SS, Park SK, Yhim HY, Kim MK, Jo JC, Mun YC, Lee JH, Kim JS; Korean Multiple Myeloma Working Party. Oncotarget. 2017 Jun 16;8(45):79517-79526 |
| 2017 | Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG. Br J Haematol. 2017 Oct;179(1):66-74 |
| 2017 | Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Leukemia. 2017 May 12. doi: 10.1038/leu.2017.138. [Epub ahead of print] |
| 2017 | Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients Treated with Novel Agents as a Primary Therapy. Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS, Jo JC, Kang HJ, Mun YC, Lee WS, Lee JJ, Suh C, Kim K; Korean Multiple Myeloma Working Party. Am J Hematol. 2017 Dec;92(12):1280-1286 |
| 2017 | Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Seo J, Kim WS, Kim JS, Kim SJ, Lee JH, Hong JS, Lee GW, Oh SY, Lee JH, Yoon DH, Lee WS, Kim HJ, Kwak JY, Kang HJ, Jo JC, Park Y, Lee HS, Kim HJ, Suh C. Blood Res. 2017 Sep;52(3):200-206 |
| 2017 | Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. Choi CW, Jang JH, Kim JS, Jo DY, Lee JH, Kim SH, Kim YK, Won JH, Chung JS, Kim H, Lee JH, Kim MK, Eom HS, Hyun SY, Kim JA, Lee JW. Blood Res. 2017 Sep;52(3):207-211. |
| 2017 | Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Oncotarget. 2017 Sep 18;8(54):92171-92182. |
| 2016 | Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia. Hong J, Woo HS, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Support Care Cancer. 2016 Jan;24(1):187-94. |
| 2016 | Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Kim YS, Cho EK, Woo HS, Hong J, Ahn HK, Park I, Sym SJ, Kyung SY, Kang SM, Park JW, Jeong SH, Park J, Lee JH, Shin DB. Cancer Res Treat. 2016;48(1)80-87 |
| 2016 | Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment. Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Blood. 2016 Feb 11;127(6):713-21 |
| 2016 | Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Lancet Oncol. 2016 Jan;17(1):27-38 |
| 2016 | Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. N Engl J Med. 2016, 28;374(17):1621-34 |
| 2016 | Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Korean J Intern Med. 2016 Apr 20 |
| 2016 | Prgostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with Gemcitabine-Based Chemotherapy. Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Cancer Res Treat. 2016 Mar 23 |
| 2016 | A successful planned pregnancy and delivery with eculizumab maintenance in a woman with Paroxysmal Nocturnal Hemoglobinuria. Eun Yeong Cho1, Ae Jin Kim1, Ji Yong Jung1, Jeong Yeal Ahn2, Suk Young Kim3, and Jae Hoon Lee. Suncheonhyang Med Science 2016; 22(1):50-53, 2016 |
| 2016 | Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: Granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. Jang JE, Cheong JW, Kim SJ, Cho H, Suh C, Lee H, Eom HS, Yhim HY, Lee WS, Min CK, Lee JH, Park JS, Kim JS. Leuk Lymphoma. 2016 Jun;57(6):1389-97 |
| 2016 | Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. Hong J, Lee S, Chun G, Jung JY, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Blood Research 2016 Jun;51(2):113-21 |
| 2016 | Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. Jeong JH, Lee HT, Seo JY, Seo YH, Kim KH, Kim MJ, Lee JH, Park J, Hong JS, Park PW, Ahn JY. Ann Lab Med. 2016 Jul;36(4):291-9. |
| 2016 | Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study. Byun JM, Kim YJ, Yoon HJ, Kim SY, Kim HJ, Yoon J, Min YH, Cheong JW, Park J, Lee JH, Hong DS, Park SK, Kim HJ, Ahn JS, Shin HJ, Chung JS, Lee WS, Lee SM, Park Y, Kim BS, Lee JH, Lee KH, Jung CW, Jang JH, Min WS, Park TS; AML/MDS working party of Korean Society of Hematology. Ann Hematol. 2016 Aug;95(8):1223-32 |
| 2016 | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Yoon DH, Kim SJ, Jeong SH, Shin DY, Bae SH, Hong J, Park SK, Yhim HY, Yang DH, Lee H, Kang HJ, Lee MH, Eom HS, Kwak JY, Lee JH, Suh C, Kim WS. Oncotarget. 2016 Aug 16. doi: 10.18632/oncotarget.11319. [Epub ahead of print] |
| 2016 | Recent Advances in Multiple Myeloma: a Korean Perspective. Hong J and Lee JH. Korean J Intern Med 2016 Sep;31(5):820-34 |
| 2016 | Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK; Korean Multiple Myeloma Working Party. Blood Res. 2016 Sep;51(3):193-199. |
| 2016 | Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi: 10.1016/S2352-3026(16)30147-8 |
| 2016 | Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Cancer Res Treat. 2016 Oct;48(4):1264-1273 |
| 2016 | Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Kwon J, Min CK, Kim K, Han JJ, Moon JH, Kang HJ, Eom HS, Kim MK, Kim HJ, Yoon DH, Lee JO, Lee WS, Lee JH, Lee JJ, Choi YS, Kim SH, Yoon SS. Cancer Med. 2016 Dec 1. doi: 10.1002/cam4.970. [Epub ahead of print] |
| 2016 | Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. Suh KJ, Cheong JW, Kim I, Kim HJ, Shin DY, Koh Y, Yoon SS, Min YH, Ahn JS, Kim YK, Lee YG, Lee JO, Bang SM, Mun YC, Seong CM, Park Y, Kim BS, Hong J, Park J, Lee JH, Kim SY, Lee HG. PLoS One. 2016 Nov 8;11(11):e0166245. doi: 10.1371/journal.pone.0166245 |
| 2016 | A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer. Sym SJ, Hong J, Jung M, Koo YS, Park YH, Kim KK, Park J, Cho EK, Lee JH, Shin D. J Clin Oncol. 2012 Feb;30(4_suppl):344. |
| 2015 | Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea.Kim HJ, Yoon SS, Eom HS, Kim K, Kim JS, Lee JJ, Bang SM, Min CK, Park JS, Lee JH; Korean Multiple Myeloma Working Party.Blood Res. 2015 Mar;50(1):7-18.. Review |
| 2015 | Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. Song MK, Chung JS, Lee JJ, Lee JH, Song IC, Lee SM, Shin DY, Lee GW, Lee IS. Acta Haematol. 2015;134(1):7-16 |
| 2015 | Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Hong J, Kim SJ, Ahn JS, Song MK, Kim YR, Lee HS, Yhim HY, Yoon DH, Kim MK, Oh SY, Park Y, Mun YC, Do YR, Ryoo HM, Lee JJ, Lee JH, Kim WS, Suh C. Cancer Res Treat. 2015 Apr;47(2):173-81 |
| 2015 | Nilotinib combined with multi-agent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH. Blood. 2015 ;126(6) : 746-56 |
| 2015 | A Case of Primary Breast Diffuse Large B-Cell Lymphoma Treated with Chemotherapy Followed by Elective Field Radiation Therapy: A Brief Treatment Pattern Review from a Radiation Oncologist’s Point of View. Kyu Chan Lee, Seung Heon Lee, KiHoon Sung, So Hyun Ahn, Jinho Choi, Seok Ho Lee, Jae Hoon Lee, Junshik Hong, and Sang Hui Park. Case Reports in Oncological MedicineVolume 2015 (2015) |
| 2015 | Long-term follow-up of imatinib plus combination chemotherapy in for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Lim SN, Joo YD, Lee KH, Kim DY, Lee JH, Lee JH, Chi HS, Yun SC, Lee WS, Lee SM, Park S, Kim I, Sohn SK, Moon JH, Ryoo HM, Bae SH, Hyun MS, Kim MK, Kim HJ, Yang DH, Eom HS, Lee GW, Jung CW, Won JH, Kim H, Lee JH, Shin HJ, Jang DY. Am J Hematol. 2015, Nov; 90(11): 1013-20 |
| 2015 | Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1. |
| 2015 | Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy. Park S, Hong J, Hwang I, Ahn JY, Cho EY, Park J, Cho EK, Shin DB, Lee JH. J Geriatr Oncol. 2015 Nov;6(6):470-8. |
| 2015 | Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study. Kim YS, Sym SJ, Baek MY, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Cancer Chemother Pharmacol. 2015 Dec;76(6):1267-72. |
| 2015 | Successful Treatment with Low-dose Rituximab in a Patient with Plasma Exchange-refractory Idiopathic Thrombotic Thrombocytopenic Purpura. Song KH, Hong J, Hwang H, Park J, Ahn JY, Lee JH Korean J Int Med 2015;89(6):709-713 |
| 2014 | A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH , Shin DB. Cancer Chemother Pharmacol. 2014 2014 Jan;73(1):163-9. |
| 2014 | High-dose Etoposide plus G-CSF as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma (CISL) Hyun SY, Cheong JW, Lim SJ, Min YH, Yang DH, Ahn JS, Ryoo HM, Do YR, Lee HS, Lee JH , Oh SY, Suh C, Yhim HY, Kim JS. Biol BMT 2014 Jan ;20(1):73-9 |
| 2014 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. Kim K, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH , Min CK; Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2014 Jan ;93(1):113-121] |
| 2014 | Acute myeloid leukemia with persistent marrow aplasia after chemotherapy treated with reduced intensity allo-stem cell transplantation. Yoon H, Hong J, Kim S, Lee DM, Park J, Ahn JY, Lee JH. KJIM 2013;86(2):242-6 |
| 2014 | IMWG consensus on risk stratification in multiple myeloma. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. Leukemia. 2014 Feb;28(2):269-77 |
| 2014 | Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Tumour Biol. 2014 Jun;35(6):5735-40. |
| 2014 | Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis. Yi HG, Lee MH, Kim CS, Hong J, Park J, Lee JH, Han BR, Kim HY, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY, Gyeonggi/Incheon Branch, The Korean Society of Hematology. Blood Res. 2014 Jun;49(2):95-99. |
| 2014 | Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH , Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH; Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party. Transfusion. 2014 June;54(6):1542-51 |
| 2014 | Clinical profiles of multiple myeloma in Asia - an Asian Myeloma Network (AMN) study. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim J, Nawarawong W, Siritanaratkul N, Durie BG. Am J Hematol. 2014 Jul;89(7):751-6. |
| 2014 | Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Oh S, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim CS, Mun YC, Kim, Lee DS, Lee JH. ; the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol 2014 Aug;93(8):1353-61. |
| 2014 | Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients. Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH, Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, Bang SM, Park J, Lee JH, Lee WS, Joo YD, Maeng CH, Yoon HJ, Lee NR, Kwak JY, Kim KH, Won JH, Han BR, Zang DY, Moon JH, Sohn SK, Bae SH, Ryoo HM, Kim SY, Lee MH, Min YH; The Korean Society of Hematology AML/MDS Working Party. Int J Hematol. 2014 Aug;100(2):141-51 |
| 2014 | Prognostic Value of Metabolic Tumor Volume Estimated by 18F-FDG Positron Emission Tomography/Computed Tomography in patients with diffuse large B-cell lymphoma of stage II or III disease. Kim J, Hong J, Kim SG, Hwang KH, Kim M, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Nuclear Medicine and Molecular Imaging 2014 Sep;48(3):187-95. |
| 2014 | Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal |
